These results indicated the possibility that in EGFR-mutated NSCLC, the immune escape in the oncogenic activation of the EGFR pathway is mainly mediated by the upregulation of PD-L1 through EGFR activation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.